There are many options available for onychomycosis treatment, but the drug is prescribed by physicians is the first line of treatment. The success rate of drugs for onychomycosis treatment is 40-50% as single therapy, whereas, the combination of onychomycosis treatment with photodynamic therapy is the most successful option. Also, the cost of drugs is much cheaper as compared to laser and photodynamic therapy, which has increased its preference among patients seeking onychomycosis treatment.
The drugs segment by treatment type in the onychomycosis treatment market is the leading segment in terms of revenue, and it is estimated to gain more than 80% of revenue share over the forecast period. Distal subungal onychomycosis is the most prevalent type of onychomycosis. Hence, this segment is expected to be a prominent segment by indication in the global onychomycosis treatment market. The prevalence of onychomycosis is much higher in males than females. Therefore, by gender, the male segment is estimated to generate greater revenue than female segment. The availability of favorable reimbursements in the U.S. is fueling the growth of onychomycosis treatment market in North America. Therefore, the North America onychomycosis treatment market had a 45.5% market value share in 2017, and anticipated to reach a market value of US$ 4,142.3 Mn by 2028.
FMI’s report tracks some of the prominent companies involved in the onychomycosis treatment market, such as Valeant Pharmaceuticals Inc., Galderma S.A., Novartis AG, Pfizer, Inc., Moberg Pharma AB, Johnson & Johnson Services, Inc., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Medimetriks Pharmaceuticals, Inc., Lumenis Ltd., Biofrontera AG, Bayer AG, and Leo Pharma A/S.